Nuclear Medicine & Theranostics
Radioligand therapy dosing and scintigraphy scoring.
Determines whether lutetium Lu-177 dotatate (Lutathera) should be continued at full activity, withheld and resumed at 3.7 GBq, or permanently discontinued, based on the type and severity of an adverse reaction.
Maps adverse reactions during lutetium Lu-177 vipivotide tetraxetan (Pluvicto) therapy to the prescribing-information actions: continue, withhold, reduce the dose once by 20% to 5.9 GBq, or permanently discontinue.
Sums MIBG-avid disease burden across nine skeletal zones plus a soft-tissue zone, each graded 0-3, to yield the Curie score (0-30) used for neuroblastoma staging, response assessment, and prognosis.
Categorizes FDG-PET treatment response (CMR, PMR, SMD or PMD) from the change in peak standardized uptake value corrected for lean body mass (SULpeak), with an optional James-formula lean body mass helper.
Scores the most intense residual FDG uptake on a lymphoma PET/CT against the mediastinal blood pool and liver (Deauville 1-5, with suffix X) and maps the score plus its change from baseline to the Lugano metabolic response category.
Assigns the lesion-level PSMA-RADS version 1.0 category for a finding on PSMA-targeted PET. Returns the official likelihood-of-malignancy wording and the recommended next step (observation, follow-up, biopsy, or treat as disease).
Builds a standardized PROMISE molecular-imaging TNM (miTNM) stage from PSMA-PET findings. Select miT, miN, and miM (including bone-pattern subtypes) to generate the composite stage string, plain-language interpretation, and management-oriented notes aligned with PROMISE V2 / EAU-EANM reporting.